Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

NCT02093819 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

NCT02044406 ·Status: COMPLETED ·Phase: PHASE1

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

NCT04366622 ·Status: COMPLETED ·Phase: PHASE1

Single Rising Dose Study of BI 690517 in Healthy Volunteers

NCT02891148 ·Status: COMPLETED ·Phase: PHASE1

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

NCT05661344 ·Status: COMPLETED ·Phase: PHASE1

A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

NCT03773068 ·Status: COMPLETED ·Phase: PHASE1

Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

NCT02191865 ·Status: COMPLETED ·Phase: PHASE1

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

NCT01763333 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

NCT07102095 ·Status: COMPLETED ·Phase: PHASE1

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

NCT01853800 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers

NCT01541488 ·Status: COMPLETED ·Phase: PHASE1

First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784

NCT02212080 ·Status: COMPLETED ·Phase: PHASE1

Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food

NCT01286571 ·Status: COMPLETED ·Phase: PHASE1

BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect

NCT03212586 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

NCT02068690 ·Status: COMPLETED ·Phase: PHASE1

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

NCT05731908 ·Status: COMPLETED ·Phase: PHASE1

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

NCT03842761 ·Status: COMPLETED ·Phase: PHASE1

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

NCT02265653 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

NCT06444204 ·Status: COMPLETED ·Phase: PHASE1

Safety Tolerability and Pharmacokinetic of BI 411034

NCT01581684 ·Status: COMPLETED ·Phase: PHASE1

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

NCT02367027 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability of BI 685509 in Healthy Subjects

NCT03116906 ·Status: COMPLETED ·Phase: PHASE1

Investigation of Single Rising Doses of BI 685509

NCT02694354 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

NCT01737996 ·Status: COMPLETED ·Phase: PHASE1